ALFA Finder| Revenue growth | FY26 revenue doubled to INR 2,300cr from INR 1,085cr in FY25. |
|---|---|
| Margins | FY26 PAT margin at 27-28%; EBITDA at 38-39%. |
| Order book | Full for next six months; avoiding low-margin high-volume orders. |
| Demand visibility | Strong; order book for Caplin Steriles full for almost six months. |
| Management confidence | High; citing 'anti-fragile' model and strong cash reserves for inorganic growth. |
Growth
FY26 Revenue doubled to INR 2,300cr; EBITDA, PBT, and PAT all increased 2.5x year-over-year.
Outlook
Targeting 17 injectable lines in 2-3 years; INR 510cr residual capex planned for FY27-28.
Risks
Global geopolitical tensions impacting API/solvent costs and freight; currency volatility in Latin American markets.
Earnings Call filed with BSE, NSE: CAPLIPOINT. Summary written with AI assistance from the document.
Caplin Point Laboratories Ltd: key numbers
- Share price
- ₹2,557.80
- Market cap
- ₹19,442 Cr
- Revenue (annual)
- ₹2,187 Cr
- Net profit (annual)
- ₹641.2 Cr
- P/E (TTM)
- 29.2×Sector 43.8×
- Promoter holding
- 70.57%+0.00% QoQ
- FII holding
- 5.72%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Caplin Point Laboratories Ltd
All →Caplin Point Laboratories Board Meeting Date
Caplin Point schedules a 12 November 2026 board meeting for unaudited quarterly and half-year results. The trading window stays closed until 14 November 2026.
Caplin Point Laboratories Other Announcement
Caplin Point Laboratories Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI listing regulations.
Caplin Point Laboratories Annual General Meeting
Caplin Point Laboratories concluded its 35th Annual General Meeting on September 25, 2026. Key business included adopting financial statements and approving the final dividend declaration.
Caplin Point Laboratories Price Movement Clarification
Caplin Point Laboratories clarified that the recent increase in its stock's trading volume is market-driven. The company confirmed no undisclosed material information exists regarding this movement.
Caplin Point Laboratories Other Announcement
Caplin Point Laboratories Limited shared a weblink for its 35th AGM Notice and Annual Report for FY 2025-26. The communication targets shareholders with unregistered email addresses.
Caplin Point Laboratories Annual General Meeting
Caplin Point Laboratories Limited scheduled its 35th Annual General Meeting for September 25, 2026. Key agenda items include adopting financial statements and declaring a ₹4 final dividend.